American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
The Regulator · Thursday, November 19, 2026

The Regulator

Rules. Money. Medicine. Decoded daily.
5 stories · 4 min read
Reading as

$798 million a year: that is the savings the Department of Health and Human Services (HHS) projects from its final HIPAA Privacy Rule overhaul, which publishes today and cuts the deadline to answer a patient’s records request from 30 days to 15. The Office for Civil Rights rule takes effect January 19, 2027, and covered entities must comply by July 19, 2027. It adds definitions of “electronic health record” and “personal health application,” requires providers and plans to post estimated fee schedules for copies of records on their websites, and ends the requirement that direct-treatment providers seek a patient’s written acknowledgment of the Notice of Privacy Practices. It also clarifies that covered entities may disclose health information to social services agencies, community-based organizations and home and community-based services providers for individual-level care coordination. HHS counts 847,506 covered-entity business establishments and puts annualized costs at $252.33 million against annualized savings of $798.13 million, a net $545.79 million at a 7 percent discount rate, plus first-year administrative costs of about $132.68 million. Several proposals did not survive, including a minimum-necessary exception and broader disclosures to family and friends. Who it hits: hospitals, physician practices, health plans and pharmacies, which must rewrite privacy notices, retrain staff and speed up records fulfillment by July 19, 2027. Confidence: High on the rule’s terms and dates; Med on the savings, which are HHS’s own projections. Sources: Federal Register final rule, 91 FR 74848 (document 2026-23429).

The Centers for Medicare & Medicaid Services (CMS) fraud rule we covered yesterday is now in the Federal Register, and the comment clock runs to January 19, 2027. The proposed rule, “Comprehensive Regulations To Uncover Suspicious Healthcare,” publishes today. It proposes changes to provider enrollment, medical review and investigations across Medicare, Medicaid, the Children’s Health Insurance Program and the ACA marketplace. Who it hits: Medicare Advantage plans, their contracted providers, state Medicaid agencies and any supplier with a revocation history, all of whom now have a firm date to file comments. Confidence: High on the publication and deadline; we cite the Federal Register’s abstract and dates here, not the full text. Sources: Federal Register proposed rule, document 2026-23461.

Medicare’s 2027 premium and deductible notices are now official: $209.40 a month for Part B and a $1,776 hospital deductible. CMS’s notices appear in today’s Federal Register, and the published figures match what the agency filed for inspection November 17. The standard Part B premium is $209.40, up $6.50 from $202.90, with a $292 deductible. The Federal Register entry adds the monthly actuarial rates, $418.70 for aged enrollees and $452.40 for disabled enrollees, which set the base the premium is derived from. Part A hospital days 61 to 90 cost $444 a day, lifetime reserve days $888, and skilled nursing facility days 21 to 100 $222. The Part A premium for people without enough work history is $597 a month, or $328 for certain others. All take effect January 1, 2027. Who it hits: every Medicare enrollee, plus Medigap and retiree plans that price off these amounts. Confidence: High. Sources: Part B premium notice, document 2026-23601, Part A deductible notice, document 2026-23603, Part A premium notice, document 2026-23604.

FDA approved Infilbray (venglustat), the first drug for the neurological symptoms of type 3 Gaucher disease. The Food and Drug Administration (FDA) approved the tablet November 18 for adults and children weighing at least 15 kilograms. Gaucher disease is an inherited enzyme disorder. The approval rests on a randomized, double-blind study of 43 patients aged 12 and older who took the tablet or received intravenous enzyme replacement every two weeks for 52 weeks, and the tablet group did better on a combined neurological measure at Week 52. The label carries a risk of serious psychiatric events, including suicidal thoughts and behavior. The drug, made by Genzyme, a Sanofi company, had Orphan Drug and Priority Review designations. Who it hits: the small population with type 3 disease, and payers that will price a rare-disease therapy. FDA’s release gives no price. Confidence: High on the approval and study design; Low on cost. Sources: FDA news release.

The HHS inspector general named five problem areas for the department, led by Medicare and Medicaid. The Office of Inspector General (OIG) posted its 2026 Top Management and Performance Challenges report November 17. The five sections are Medicare and Medicaid, Grants and Contracts, Public Health, Beneficiary Health and Safety, and Technological Advancement and Cybersecurity. The report is the inspector general’s own list of where HHS programs are most exposed, which tends to steer later audits and investigations. Who it hits: HHS program offices, grantees and contractors, and Medicare and Medicaid providers. We confirmed the report and its structure from OIG’s page but could not read the full text this run, so we give no figures. Confidence: Med. Sources: HHS OIG report page.

Quiet note: the rest of today’s HHS filings in the Federal Register were National Institutes of Health meeting notices, a CMS quarterly list of program issuances, FDA information-collection notices (including the National Youth Tobacco Survey, comments due December 21), and a technical correction to HHS acquisition regulations. We found no verified state-level action or court ruling dated in the last 48 hours, so there is no state or court item today.

Get tomorrow's edition in your inbox.

Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.

Where these stories are tracked
CMS fraud rule comment deadline Rule tracked on Rule tracker Open →
First drug for type 3 Gaucher neurology Approval tracked on Approvals Open →
2027 Medicare cost notices official Rule tracked on Rule tracker Open →
HHS watchdog names five problem areas Report tracked on Findings Open →
Get the next issue Free, daily